Irinotecan plus cetuximab rechallenge versus trifluridine/tipiracil plus bevacizumab in metastatic colorectal cancer

Is this trial a fit for you?

A plain-English reading of the study's rules. Only the study team can confirm whether you qualify.

What this trial studies

This is a randomized, open-label phase II study enrolling patients with metastatic colorectal cancer who previously benefited from anti-EGFR therapy and have progressed after prior lines of treatment. Participants are selected based on circulating tumor DNA to be wild-type for several genes and without HER2 amplification. They will be randomized 1:1 to receive either cetuximab with irinotecan or trifluridine/tipiracil with bevacizumab, continued until progression or unacceptable toxicity. Tumor response will be assessed by RECIST 1.1, with secondary endpoints including progression-free survival, overall survival, safety, and quality of life.

Why it matters

Who can join: the full rules

Inclusion Criteria:

1. Male or female aged ≥18 years
2. Eastern Cooperative Oncology Group Performance Status (ECOG-PS) ≤1
3. Diagnosis of histologically or cytologically confirmed colorectal cancer.
4. At least one measurable lesion according to RECIST1.1
5. KRAS/NRAS/BRAFV600E wt status of primary CRC or related metastasis (local laboratory assessment).
6. Progression to previous first-line anti-EGFR-containing therapy producing at least a partial response ≥ 6 months.
7. Received and progressed to an anti-EGFR and irinotecan free second-line treatment.
8. Have an anti-EGFR free interval of at least 4 months.
9. Refractory to previous 5-fluorouracil/capecitabine, irinotecan, oxaliplatin, bevacizumab.
10. RAS/BRAF/EGFR/PIK3CAex20/MAP2K1/MET WT and HER2 not amplified ctDNA at FoundationOne CDx test at baseline.
11. Life expectancy of at least 3 months.
12. Adequate hematological function defined by white blood cell (WBC) count ≥ 2.5 × 109/L with absolute neutrophil count (ANC) ≥ 1.5 × 109/L, lymphocyte count ≥ 0.5 × 109/L, platelet count ≥ 100 × 109/L, and hemoglobin ≥ 9 g/dL (may have been transfused).
13. Adequate hepatic function defined by a total bilirubin level ≤ 1.5 × the upper limit of normal (ULN) range and AST and alanine aminotransferase (ALT) levels ≤ 2.5 × ULN for all subjects or AST and ALT levels ≤ 5 x ULN (for subjects with documented metastatic disease to the liver).
14. Adequate renal function defined by an estimated creatinine clearance \> 30 mL/min according to the Cockcroft-Gault formula (or local institutional standard method).
15. No contraindication to the study drugs.
16. No prior treatment with trifluridine/tipiracil.
17. Women of childbearing potential\* must have a negative blood pregnancy test at thescreening visit. Subjects and their partners must be willing to avoid pregnancy during the trial.

    \*A woman is considered of childbearing potential (WOCBP), i.e. fertile, following menarche and until becoming post-menopausal unless permanently sterile. Permanent sterilisation methods include hysterectomy, bilateral salpingectomy and bilateral oophorectomy.
18. Women of childbearing potential, or male, must agree to use adequate contraception (e.g., abstinence, intrauterine device, oral contraceptive, or double-barrier method), during the study and until at least 6 months after last dose of study treatment administration, based on the judgment of the Investigator or a designated associate.
19. Will and ability to comply with the protocol.
20. Signed informed consent obtained before screening.

Exclusion Criteria:

1. ECOG PS ≥2
2. Received more than 2 lines of treatment for metastatic disease.
3. Previous treatment with trifluridine/tipiracil
4. RAS/BRAF/EGFR/PIK3CAex20/MAP2K1/MET WT HER2 not amplified status at liquid biopsy analysis during screening.
5. Previous history of malignancy within the last 2 years will be excluded with the exception of localized basal and squamous cell carcinoma or cervical cancer in situ
6. Evidence of bleeding diathesis or coagulopathy.
7. Uncontrolled hypertension and prior history of hypertensive crisis or hypertensive encephalopathy.
8. Known severe hypersensitivity to investigational product or any component in its formulations, including known severe hypersensitivity reactions to monoclonal antibodies (NCI CTCAE v 5 Grade ≥ 3), any history of anaphylaxis, or uncontrolled asthma (that is, 3 or more features of partially controlled asthma).
9. Clinically significant cardiovascular disease, active inflammatory bowel disease, active autoimmune disease.
10. Diagnosis of interstitial pneumonitis or pulmonary fibrosis.
11. History of abdominal fistula, GI perforation, intra-abdominal abscess or active gastrointestinal bleeding within 6 months prior to the first study treatment.
12. Pregnant or lactating women.
13. Psychiatric or addictive disorders would preclude study participation.
14. Active uncontrolled infections or other clinically relevant concomitant illness contraindicating study treatments.
15. Withdrawal of the consent to take part to the study.

Where it's running

• Azienda Ospedaliero Universitaria "SS Antonio e Biagio e Cesare Arrigo"
  Alessandria, Italy Recruiting
• A.O.U. Ospedali Riuniti
  Ancona, Italy Recruiting
• Centro di Riferimento Oncologico (CRO), IRCCS
  Aviano, Italy Recruiting
• A.O.R.N. "Sant'anna e San Sebastiano"
  Caserta, Italy Recruiting
• A.O.U. Careggi
  Florence, Italy Recruiting
• Istituto Romagnolo per lo Studio dei Tumori 'Dino Amadori'
  Meldola, Italy Recruiting

Study contacts

• Study coordinator: Davide Ciardiello DC Principal Investigator
• Email: davide.ciardiello@ieo.it
• Phone: 02/94372686

Similar studies

Other studies for the same condition or treatment. Recruiting studies are listed first.

• HSK42360-Na tablets with cetuximab in BRAF V600-mutant metastatic colorectal cancer

  This Phase 1/2 study tests whether HSK42360-Na tablets with cetuximab, with or without standard chemotherapy, are safe and may help people whose colorectal cancer has a BRAF V600 mutation that has spread.

  Recruiting Phase 1/2 Haisco Pharmaceutical Group Co., Ltd. · Beijing · NCT07790510

• Petosemtamab plus chemotherapy vs standard chemo plus cetuximab or bevacizumab in RAS/BRAF WT colorectal cancer

  This phase 3 trial tests whether adding petosemtamab to standard chemotherapy works better than the usual chemo plus cetuximab or bevacizumab for people with recurrent, unresectable, or metastatic colorectal cancer that is KRAS/NRAS/BRAF wild type.

  Recruiting at 5 sites Phase 3 Genmab · Hot Springs, Arkansas and 4 other locations · NCT07775287

• Bevacizumab, sintilimab, cetuximab and irinotecan in refractory RAS wild-type metastatic colorectal cancer

  This trial tests whether adding sintilimab to a cetuximab and irinotecan backbone, with or without bevacizumab, helps patients with heavily pretreated metastatic colorectal cancer that has RAS wild-type tumors.

  Recruiting Phase 2 Guangdong Provincial People's Hospital · Guangzhou, Guangdong · NCT07722754

• Second-line combination treatment for MSS metastatic colorectal cancer

  This trial will try folinic acid plus continuous 5-FU with liposomal irinotecan, sometimes combined with cetuximab or bevacizumab, as a second-line option for adults with MSS metastatic colorectal cancer who progressed on or cannot tolerate oxaliplatin-based therapy.

  Recruiting Phase 2 The First Hospital of Jilin University · Changchun, Jilin · NCT07559760

• Short-course radiotherapy plus intensified chemotherapy and targeted therapy with immunotherapy for high-risk rectal cancer

  This trial tests whether adding targeted therapy and a PD-1 inhibitor to a short course of radiotherapy and standard chemotherapy helps high-risk pMMR/MSS rectal cancer patients, compared with the same radiotherapy and chemotherapy alone.

  Recruiting Phase 3 Sixth Affiliated Hospital, Sun Yat-sen University · Guangzhou, Guangdong · NCT07549399

• SAR445877 with FOLFOX6 and bevacizumab as first-line treatment for MSS metastatic colorectal cancer

  This study tests whether giving SAR445877 together with FOLFOX6 and bevacizumab is safe and tolerable as a first-line treatment for adults with MSS metastatic colorectal cancer.

  Recruiting Phase 1 M.D. Anderson Cancer Center · Houston, Texas · NCT07500298

How to take part

1. Review the eligibility criteria above with your treating physician.
2. Check the official listing on ClinicalTrials.gov for the latest contact details and recruitment status.
3. Contact the study coordinator or principal investigator to ask for pre-screening. Pre-screening is free and never obligates you to enroll.